1-[4-(6-fluoro-3-oxo-10-aza-3-azoniatricyclo[6.4.1.04,13]trideca-4,6,8(13)-trien-10-yl)phenyl]-N-methylmethanamine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯氮卓类
• 英文名称: 1-[4-(6-fluoro-3-oxo-10-aza-3-azoniatricyclo[6.4.1.04,13]trideca-4,6,8(13)-trien-10-yl)phenyl]-N-methylmethanamine
• 化学式: C19H21FN3O+
• 分子量: 326.4
• InChiKey: OCPLCICJVCCSMO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  24
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.37
• 拓扑面积：
  35.4
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• Compositions to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof
  申请人：Race Oncology Ltd.

  公开号：US11135201B2

  公开（公告）日：2021-10-05

  The present invention describes methods and compositions for improving the therapeutic efficacy of therapeutic agents previously limited by suboptimal therapeutic performance by either improving efficacy as monotherapy or reducing side effects. Such methods and compositions are particularly applicable to bisantrene or derivatives, analogs, or prodrugs thereof. Such methods and compositions are particularly useful for treatment of malignancies.

  本发明描述了通过提高单一疗法的疗效或减少副作用来改善以前因治疗效果不理想而受到限制的治疗剂的疗效的方法和组合物。这种方法和组合物特别适用于双蒽或其衍生物、类似物或原药。此类方法和组合物尤其适用于恶性肿瘤的治疗。
• Use of substituted hexitols including dianhydrogalactitol and analogs to treat neoplastic disease and cancer stem cells including glioblastoma multiforme and medulloblastoma
  申请人：Del Mar Pharmaceuticals (BC) Ltd.

  公开号：US11234955B2

  公开（公告）日：2022-02-01

  The use of dianhydrogalactitol provides a novel therapeutic modality for the treatment of glioblastoma multiforme and medulloblastoma. Dianhydrogalactitol acts as an alkylating agent on DNA that creates N7 methylation. Dianhydrogalactitol is effective in suppressing the growth of cancer stem cells and is active against tumors that are refractory to temozolomide; the drug acts independently of the MGMT repair mechanism.

  二氢半乳糖醇的使用为治疗多形性胶质母细胞瘤和髓母细胞瘤提供了一种新的治疗方法。二氢半乳糖醇是一种 DNA 烷基化剂，可产生 N7 甲基化。Dianhydrogalactitol 能有效抑制癌症干细胞的生长，并对替莫唑胺难治性肿瘤有效；该药物的作用不受 MGMT 修复机制的影响。
• THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS
  申请人：Brown, Dennis M.

  公开号：EP2983674A1

  公开（公告）日：2016-02-17
• COMPOSITIONS TO IMPROVE THE THERAPEUTIC BENEFIT OF BISANTRENE
  申请人：Update Pharma Inc.

  公开号：EP3024457A1

  公开（公告）日：2016-06-01
• COMBINATORIAL METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF BISANTRENE
  申请人：Update Pharma Inc.

  公开号：EP3024456A1

  公开（公告）日：2016-06-01